Inhibition of vasoconstrictor responses by 6-keto-PGE1 in the feline mesenteric vascular bed.
The effects of 6-keto-PGE1 on vascular resistance and vascular responses to sympathetic nerve stimulation and vasoconstrictor hormones were investigated in the feline mesenteric vascular bed. Infusions of 6-keto-PGE1 into the superior mesenteric artery dilated the mesenteric vascular bed and markedly inhibited vasoconstrictor responses to sympathetic nerve stimulation, norepinephrine and angiotensin II. The effects of 6-keto-PGE1 and PGE1 on vascular resistance and vasoconstrictor responses were quite similar and both substances inhibited responses to nerve stimulation and pressor hormones in a reversible manner. Responses to nerve stimulation, norepinephrine and angiotensin II were inhibited to a similar extent during infusion of 6-keto-PGE1 and PGE1. Results of these studies suggest that 6-keto-PGE1, a newly identified prostaglandin metabolite, and PGE1 possess the ability to inhibit the vasoconstrictor effects of sympathetic nerve stimulation and pressor hormones by a non-specific action on vascular smooth muscle in the feline small intestine.
D015121:6-Ketoprostaglandin F1 alpha; D000818:Animals; D001794:Blood Pressure / Q000187:drug effects; D002415:Cats; D004558:Electric Stimulation; D011464:Epoprostenol / Q000494:pharmacology; D005260:Female; D007269:Injections, Intra-Arterial; D008297:Male; D008638:Mesenteric Arteries / Q000187:drug effects*; D010477:Perfusion; D011458:Prostaglandins E / Q000494:pharmacology; D011460:Prostaglandins F / Q000008:administration & dosage / Q000494:pharmacology*; D014655:Vascular Resistance / Q000187:drug effects; D014661:Vasoconstriction / Q000187:drug effects*
D011458:Prostaglandins E; D011460:Prostaglandins F; D015121:6-Ketoprostaglandin F1 alpha; D011464:Epoprostenol